						1									once, dur	ing the repo	rting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the	Date of Audit	Value of	In case monies either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		102	Amount as approved by the Audit Committee.			102	-	-	-		-	-	-		-	-	-
2	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		70	Amount as approved by the Audit Committee.			70	•	-	-		-	-	-	-	-	-	-
3	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
4	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
5	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-
6	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		100	Amount as approved by the Audit Committee.			100	-	-	-		-	-	-	-	-	-	-
7	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
8	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Purchase of goods or services		25	Amount as approved by the Audit Committee.			25	-	-	-		-	-	-	-	-	-	-
9	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Purchase of goods or services		28	Amount as approved by the Audit Committee.			28	-	-	-		-	-	-	-	-	-	-
10	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-

															once, du	ing the repo	rting period v	vhen such transaction	was underta	aken.	<u>, </u>
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related party	Remarks on	Value of the related	Date of Audit Committee	Value of	In case monie either party a the trans	s a result of	m	y financials ind ake or give loa				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	transaction as approved by the audit committee	approval by audit committee	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
11	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		436	Amount as approved by the Audit Committee.			436	-	-	-		-	-	-	-	-	-	-
12	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Purchase of fixed assets		24	Amount as approved by the Audit Committee.			24	-	-	-		-	-	-	-	-	-	-
13	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-
14	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
15	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	,	-	-	-	-	-
16	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		242	Amount as approved by the Audit Committee.			242	-	-	-		-	-	-	-	-	-	-
17	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		31	Amount as approved by the Audit Committee.			31	-	-	-		-	-	-	-	-	-	-
18	Zydus Lifesciences Limited	Zydus Medtech France SAS	Subsidiary Company	Sale of goods or services		30	Amount as approved by the Audit Committee.			30	-	-	-		-	-	-	-	-	-	-
19	Zydus Lifesciences Limited	Zydus Medtech France SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	30	-		-	-	-	-	-	-	-
20	Zydus Lifesciences Limited	Vitely Corp Pvt Ltd (Formerly Known Vitely Bio LLP)	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		11	Amount as approved by the Audit Committee.			11	-	-	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period w	hen such transaction	was underta	iken.	
	Details of the party entering into the transaction	Details of the counter	party			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
21	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
22	Zydus Lifesciences Limited		Directors and/ or their relatives	Purchase of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-
23	Zydus Lifesciences Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-
24	Zydus Lifesciences Limited	International Tax & Investment Consultants- Proprietorship Firm	Directors and/ or their relatives	Purchase of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-
25	Zydus Lifesciences Limited	TUV India Private Limited	Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
26	Zydus Lifesciences Limited		Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-
27	Zydus Lifesciences Limited	Apollo Healthco Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-
28	Zydus Lifesciences Limited	Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		74	Amount as approved by the Audit Committee.			74	-	-	-		-	-	-	-	-	-	-
29	Zydus Lifesciences Limited		Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	838	Amount as approved by the Audit Committee.			838	-	-	-		-	-	-	-	-	-	-
30	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-

		T			1		,		1	ı	1		_					hen such transaction			
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related	Remarks on	Value of the related	Date of Audit Committee	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details (of loans/ inve	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	approval by audit	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
31	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-
32	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-
33	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	129	Amount as approved by the Audit Committee.			129	-	-	-		-	-	-	-	-	-	-
34	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	87	Amount as approved by the Audit Committee.			87	-	-	-		-	-	-	-	-	-	-
35	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
36	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-
37	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	73	Amount as approved by the Audit Committee.			73	-	-	-		-	-	-	-	-	-	-
38	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
39	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimbursement of Expenses paid	2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-
40	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-		-

														once, dur	ing the repo	rting period w	when such transaction	was underta	aken.	•	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials inde ake or give loar	ebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
41	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		393	Amount as approved by the Audit Committee.			393	-	-	-		-	-	-	-	-	-	-
42	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		511	Amount as approved by the Audit Committee.			511	-	-	-		-	-	-	-	-	-	-
43	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		27,247	Amount as approved by the Audit Committee.			27,247	-	-	-		-	,	-	-	-	-	-
44	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		2,292	Amount as approved by the Audit Committee.			2,292	-	-	-		-	-	-	-	-	-	-
45	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Sale of goods or services		466	Amount as approved by the Audit Committee.			466	-	-	-		-	-	-	-	-	-	-
46	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		76	Amount as approved by the Audit Committee.			76	-	-	-		-	,	-	-	-	-	-
47	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		442	Amount as approved by the Audit Committee.			442	-	-	-		-	-	-	-	-	-	-
48	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Sale of goods or services		828	Amount as approved by the Audit Committee.			828	-	-	-		-	-	-	-	-	-	-
49	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Sale of goods or services		551	Amount as approved by the Audit Committee.			551	-	-	-		-	-	-	-	-	-	-
50	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Sale of goods or services		557	Amount as approved by the Audit Committee.			557	-	-	-		-	-	-	-	-	-	-

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Nature of Details of other transaction party Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransaction during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be Closing Secured/ counterparty approved by committee ratification Opening advance/ other Cost Interest Rate (%) utilised by the Name Name the audit period issuance Tenure Tenure with the listed balance Unsecured the audit was balance intercorpora of debt/ ndebtedness Itimate recipient of committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) mount as Subsidiary Sale of goods or approved by 51 Zydus Lifesciences Limited Laboratorios Combix S.L. 306 306 the Audit Company services Committee. Amount as approved by Subsidiary Sale of goods or 52 Zydus Lifesciences Limited Zydus Worldwide DMCC 255 255 Company services the Audit Committee Amount as Zydus Lifesciences Global FZE Subsidiary Sale of goods or approved by 1,522 Zydus Lifesciences Limited 1,522 [UAE] services the Audit Company Committee Amount as 104 approved by Zydus Takeda Healthcare Sale of goods or 54 Zydus Lifesciences Limited Joint Ventures 104 rivate Limited services the Audit Committee Enterprises significantly Amount as Zydus Hospitals and nfluenced by Sale of goods or approved by 55 Zydus Lifesciences Limited Healthcare Research Private 12 12 Directors and/ services the Audit Limited or their Committee. relatives Enterprises significantly Amount as Zydus Hospitals and influenced by Sale of goods or approved by Zydus Lifesciences Limited Healthcare Research Private Directors and/ services the Audit imited or their Committee. relatives German Remedies Pharma Subsidiary N.A. 1,000 Zydus Lifesciences Limited Loan Private Limited ompany Amount as Subsidiary Purchase of fixed approved by 58 Zydus Lifesciences Limited Zydus Pharmaceuticals Limited Company the Audit assets Committee. Amount as approved by Alidac Healthcare (Myanmar) Subsidiary Sale of goods or 59 Zydus Lifesciences Limited 11 11 Limited Company services the Audit Committee Amount as Subsidiary Sale of goods or approved by Zvdus Lifesciences Limited Zvdus Wellness Limited services the Audit Company Committee Amount as Zydus Wellness Products Subsidiary Sale of goods or approved by Zydus Lifesciences Limited 11 11 mited Company ervices the Audit

Committee

														once, dur	ing the repo	rting period v	when such transaction	was underta	aken.		
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related	Dame I	Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	m	y financials inde ake or give loar				Details o	of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
62	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-
63	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-
64	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	,	-	-	-	-	-
65	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Sale of goods or services		18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-
66	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		178	Amount as approved by the Audit Committee.			178	-	-	-		-	-	-	-	-	-	-
67	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		19	Amount as approved by the Audit Committee.			19	-	-	-		-	,	-	-	-	-	-
68	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-
69	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		37	Amount as approved by the Audit Committee.			37	-	-	-		-	-	-	-	-	-	-
70	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
71	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		30	Amount as approved by the Audit Committee.			30	-	-	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period v	vhen such transaction	was underta	iken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
72	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		115	Amount as approved by the Audit Committee.			115	-	-	-		-	-	-	-	-	-	-
73	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Investment		-	N.A.	<u> </u>	 	210	1,395	1,605	-		-		Investment	N.A	N.A	Unsecured	Business Purpose
74	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	2	-		-		-	-	-	-	-
75	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
76	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	48	Amount as approved by the Audit Committee.			48	-	-	-		-	-	-	-	-	-	-
77	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.			101	-	-	-		-		-	-	-	-	-
78	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary	Loan		-	N.A.	<u> </u>	l	1,292	-	 -			-		Loans	6 Month SOFR + 240	5 Year	Unsecured	Business Purpose
79	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Company Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	1,715	3,214	-		-	-	-	-	-	-	-
80	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	160	Amount as approved by the Audit Committee.			160	-	-	-		-	-	-	-	-	-	-
81	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
82	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	10	Amount as approved by the Audit Committee.			10	-	-	-		-	-	-	-	-	-	-
83	Zydus Lifesciences Limited	Mr. Pankaj R. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			1	-	-	-		-	-	-	-	-	-	-
84	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Remuneration		-	N.A.			180	-	-	-		-	-	-	-	-	-	-
85	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Remuneration		-	N.A.			28	-	-	-		-	-	-	-	-	-	-
86	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Remuneration		-	N.A.			37	-	-	-		-	-	-	-	-	-	-

				1	,										once, dur	ing the repo	rting period v	when such transaction	was underta	aken.	Í
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	value or transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
87	Zydus Lifesciences Limited	Mr. Tushar D. Shroff	Key Managerial Personnel	Remuneration		-	N.A.			3	-	-	-		-	-	-	-	-	-	-
88	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Remuneration		-	N.A.			3	-	-	-		-	-	-	-	-	-	-
89	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
90	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.			305	-	-	-		-	-	-	-	-	-	-
91	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.			230	-	-	-		-	-	-	-	-	-	-
92	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.			314	-	-	-		-	-	-	-	-	-	-
93	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.			82	-	-			-	-	-	-	-	-	-
94	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		50	Amount as approved by the Audit Committee.			50	-	-	-		-	-	-	-	-	-	-
95	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Interest received		-	N.A.			43	-	-	-		-	-	-	-	-	-	-
96	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Interest paid		-	N.A.			34	-	-	-		-	-	-	-	-	-	-
97	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Interest paid		-	N.A.			373	-	-	-		-	-	-	-	-	-	-
98	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.			1,254	-	-	-		-	-	-	-	-	-	-
99	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited	Joint Ventures	Dividend received		-	N.A.			200	-	-	-		-	-	-	-	-	-	-
100	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Dividend received		-	N.A.			200	-	-	-		-	-	-	-	-	-	-
101	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Loan		-	N.A.			2,138	-	-	-		-	-	Loans	6 Month SONIA + 190 BPS	5 Year	Unsecured	Business Purpose
102	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
103	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	4	4	-		-	-	-	-	-	-	-
104	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Investment		-	N.A.			2,250	7,600	9,850	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
105	Zydus Lifesciences Limited	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-
106	Zydus Lifesciences Limited	Zydus Pharmaceuticals Canada Inc.	Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-
107	Zydus Lifesciences Limited	Zynext Ventures Pte. Ltd.	Subsidiary Company	Investment		-	N.A.	ļ 		-	797	-	-		-	-	-	-	-	-	-
108	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Loan		-	N.A.	ļ 		13,684	-	-	-		-	-	-	-	-	-	-
109	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.	ļ 		5,447	-	-	-		-	-	-	-	-	-	-
110	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Loan	<u> </u>	-	N.A.	<u> </u>		7,101	-	-	<u> </u>		-	-	-	-			-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of th make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction Meeting Nature approval by indebtedr Purpose for which related party ransactio during the of the (loan/ **Party Transaction** as where the transactions ratified by ess (loan/ Details of the funds will be reporting counterparty approved by committee ratification Opening Closing advance/ Secured/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) Contributions during the year Cadila Healthcare Ltd. Any other 111 Zydus Lifesciences Limited 385 Employment fincludes N.A Nanagerial Cadre EPF ransaction Benefit Plans Employee's share and contribution Contributions Cadila Healthcare Limited during the year Post Any other 112 Zydus Lifesciences Limited Employees Group Gratuity Employment [includes 16 transaction Renefit Plans Scheme Employee's share and contribution Subsidiary Any other Outstanding Zvdus Animal Health and 11,778 113 Zydus Lifesciences Limited 11,451 nvestments Limited transaction Payables - Loans Company ubsidiary Any other Outstanding Zydus Lifesciences Limited Zydus Healthcare Limited 42,347 39,280 ransaction Payables - Loan ompany German Remedies Pharma Subsidiary Any other Outstanding 115 Zvdus Lifesciences Limited N.A 1.035 1.000 Private Limited Company transaction Pavables - Loan Outstanding Subsidiary Any other 116 Zydus Lifesciences Limited Zydus Pharmaceuticals Limited Payables - Othe 442 258 N.A Company transaction than loans Outstanding Subsidiary Any other Zydus VTEC Limited 117 Zydus Lifesciences Limited Pavables - Other N.A. 11 29 Company transaction than loans Outstanding Any other Subsidiary 118 Zydus Lifesciences Limited Zydus Healthcare Limited Payables - Other 379 244 Company ransaction than loans Outstanding Zydus Pharmaceuticals (USA) Subsidiary Any other 119 Zydus Lifesciences Limited Payables - Other 650 911 N.A Company ransaction than loans Subsidiary Zydus Lifesciences Limited Zydus Healthcare (USA) LLC nvestment N.A. 221 221 Investment N.A N.A Unsecured **Business Purpose** ompany Outstanding ubsidiary Any other 121 Zydus Lifesciences Limited Zydus Healthcare (USA) LLC Payables - Other N.A 62 41 ompany ransaction than loans Outstanding ubsidiary Any other Zydus Lifesciences Limited Viona Pharmaceuticals INC Payables - Other 75 84 N.A. ransaction than loans Outstanding Subsidiary Anv other 123 Zydus Lifesciences Limited Zydus Healthcare S.A. (Pty) Ltd Payables - Other 291 NΑ 311 transaction than loans Outstanding Zydus Pharmaceuticals Mexico Subsidiary Any other 124 Zydus Lifesciences Limited Payables - Other N.A. 60 69 SA De CV Company transaction than loans Outstanding Zvdus Nikkho Farmaceutica Subsidiary Anv other 125 Zydus Lifesciences Limited Payables - Other 79 88 Company ransaction than loans Outstanding

249

318

Subsidiary

Company

Zvdus France, SAS

126 Zydus Lifesciences Limited

Any other

transaction

Payables - Other

than loans

N.A.

															once, dur	ing the repo	orting period w	hen such transaction	was underta	aken.	•
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
127	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	0	-		-	-	-	-	-	-	-
128	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-
129	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Sale of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-
130	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	5	-		-	-	-	-	-	-	-
131	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	13	13	-		-	-	-	-	-	-	-
132	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	15	65	-		-	-	-	-	-	-	-
133	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Any other transaction	Capital Advances	-	N.A.			250	-	-	-		-	-	-	-	-	-	-
134	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	7	14	-		-	-	-	-	-	-	-
135	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	-	-		-	-	-	-	-	-	-
136	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
137	Zydus Lifesciences Limited	Vitely Corp Pvt Ltd (Formerly Known Vitely Bio LLP)	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	4	-		-	-	-	-	-	-	-
138	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
139	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	3	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monies either party a the trans	s a result of		y financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
140	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	113	173			•	•	-	-	-	-	-
141	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	10	62	-		-	-	-	-	-	-	-
142	Zydus Lifesciences Limited	Aleta Hospitals LLP [Formerly known as Zydus Hospitals (Vadodara) LLP]	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
143	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	196	271	-		-	-	-	-	-	-	-
144	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	82	-	-		-	-	-	-	-	-	-
145	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	3	-	-		-	-	-	-	-	-	-
146	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	<u>-</u>	-		-	-	-	-	-	-	-
147	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	3	3	-		-	-	-	-	-	-	-
148	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	228	2,453	-		-	-	-	-	-	-	-
149	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	12,582	13,076	-		-	-	-	-	-	-	-
150	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	9,396	9,765	-		-	-	-	-	-	-	-
151	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	10,250	10,652	-		-	-	-	-	-	-	-
152	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	8,263	2,545	-		-	-	-	-	-	-	-
153	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	242	-	-		-	-	-	-	-	-	-
154	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	4	-		-	-	-	-	-	-	-

																		when such transaction			,
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related party	Remarks on	Value of the related	Date of Audit Committee	Value of	In case monie either party a the trans	s a result of	m	y financials inde ake or give loar				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	transaction as approved by the audit committee	approval by audit committee	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
155	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	13	-		-	-	-	-	-	-	-
156	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	5	8	-		-	-	-	-	-	-	-
157	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	74	20	-		-	-	-	-	-	-	-
158	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	4	-		-	-	-	-	-	-	-
159	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	295	608	-		-	-	-	-	-	-	-
160	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	14	-		-	-	-	-	-	-	-
161	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	61,770	59,596	-		-	-	-	-	-	-	-
162	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	16	-		-	-	-	-	-	-	-
163	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,797	2,285	-		-	-	-	-	-	-	-
164	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	17	55	-		-	-	-	-	-	-	-
165	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	210	499	-		-	-	-	-	-	-	-
166	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	702	316	-		-	-	-	-	-	-	-
167	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,012	1,333	-		-	-	-	-	-	-	-
168	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,371	1,638	-		-	-	-	-	-	-	-
169	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,791	2,253	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period w	hen such transaction	was underta	aken.	•
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related	Dame !	Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
170	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	893	1,377	-		-	-	,	-	-	-	-
171	Zydus Lifesciences Limited	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	76	103	-		-	-	-	-	-	-	-
172	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	96	69	-		-	-	-	-	-	-	-
173	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	248	474	-		-	-	-	-	-	-	-
174	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	409	240	-		-	-	-	-	-	-	-
175	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	74	-		-	-	-	-	-	-	-
176	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	7	-		-	-	-	-	-	-	-
177	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		10	Amount as approved by the Audit Committee.			10	-	-	-		-	-	-	-	-	-	-
178	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
179	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
180	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
181	Zydus Healthcare Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be Secured/ counterparty approved by committee ratification Opening Closing advance/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness Itimate recipient of committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) 57 approved by German Remedies Pharma Subsidiary Sale of goods or 182 Zydus Healthcare Limited 57 the Audit rivate Limited Company services Committee. Enterprises significantly Amount as Zvdus Hospitals and influenced by Sale of goods or approved by 183 Zydus Healthcare Limited Healthcare Research Private 17 Directors and/ services the Audit imited or their Committee relatives Enterprises significantly Amount as influenced by Sale of goods or approved by Ramanbhai Foundation 184 Zydus Healthcare Limited Directors and/ services the Audit or their Committee relatives Amount as Zydus Wellness Products Subsidiary Sale of goods or approved by 185 Zydus Healthcare Limited mited Company the Audit Committee Anv other Director Sitting 186 Zydus Healthcare Limited Dr. Sharvil P. Patel Managerial N.A. ransaction Any other Director Sitting Zydus Healthcare Limited Mr. Nitin D. Parekh Managerial transaction Fees Personnel Amount as Purchase of goods or approved by 188 Zydus Healthcare Limited Sterling Biotech Limited Joint Ventures the Audit Committee Outstanding Any other 189 Zydus Healthcare Limited Sterling Biotech Limited Joint Ventures Payables - Other transaction than loans Amount as approved by Subsidiary Sale of goods or 190 Zydus Healthcare Limited Zydus Foundation Company services the Audit Committee. Outstanding Subsidiary Any other 191 Zydus Healthcare Limited Zydus Foundation Receivables -N.A 0 Company transaction Other than loan: 1 Month T Bill + 35 Parent 192 1,880 Zydus Healthcare Limited N.A 5 Year Zvdus Lifesciences Limited loan Loans Unsecured **Business Purpose** ompany 1 Month T Bill + 55 193 5,000 Zydus Healthcare Limited Zydus Lifesciences Limited loan N.A Loans 5 Year Unsecured **Business Purpose** Company 1 Month T Bill + 90 arent 194 ydus Healthcare Limited Zydus Lifesciences Limited 4,075 Year Unsecured **Business Purpose** ompany Subsidiary 6 Month T Bill + 55 195 Zydus Healthcare Limited Zydus Pharmaceuticals Limited Loan N.A 1,650 Loans 6 Month Unsecured **Business Purpose** Company Subsidiary 196 Zydus Healthcare Limited ydus Pharmaceuticals Limite N.A. 1,650 Recon Pharmaceuticals and Anv other Share of profit Subsidiary Zydus Healthcare Limited

nvestments

Company

transaction

Received

															once, du	ing the repo	orting period w	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the	Date of Audit	Val of	In case monie either party a the trans	s a result of		y financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	related party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
198	3 Zydus Healthcare Limited	Zydus Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			6	-	-	-		-	-	-	-	-	-	-
199	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
200	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-
201	L Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-
202	2 Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	6	-		-	-	-	-	-	-	-
203	3 Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		38	Amount as approved by the Audit Committee.			38	-	-	-		-	-	-	-	-	-	-
204	Zydus Wellness Limited	Alidac UK Limited		Sale of goods or services		14	Amount as approved by the Audit Committee.			14	-	-	-		-	-	-	-	-	-	-
205	5 Zydus Wellness Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-
206	Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Loan		-	N.A.			350	-	-	-		-	-	-	-	-	-	-
207	7 Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
208	3 Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	358	-	-		-	-	-	-	-	-	-
209	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		1,596	Amount as approved by the Audit Committee.			1,596	-	-	-		-	-	-	-	-	-	-

									•						once, dur	ing the repo		when such transaction		aken.	•
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
210	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		32	Amount as approved by the Audit Committee.			32	-	-	-		-	-	-	-	-	-	-
211	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of fixed assets		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-
212	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		208	Amount as approved by the Audit Committee.			208	-	-	-		-	-	-	-	-	-	-
213	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest paid		-	N.A.			33	-	-	-		-	-	-	-	-	-	-
214	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			560	-	-	-		-	-	-	-	-	-	-
215	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			565	-	-	-		-	-	-	-	-	-	-
216	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			450	-	-	-		-	-	-	-	-	-	-
217	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-
218	Zydus Wellness Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
219	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.			7	-	-	-		-	-	-	-	-	-	-
220	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Remuneration		-	N.A.			15	-	-	-		-	-	-	-	-	-	-
221	· 	Mr. Nandish P. Joshi	Key Managerial Personnel	Remuneration		-	N.A.			1	-	-	-		-	-	-	-	-	-	-
222	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Interest received	ļ	-	N.A.	ļ 	ļ	9	-	-	-		-	-	-	-	-	-	-
223	Zydus Wellness Limited	Zydus Wellness International	Subsidiary Company	Loan	ļ 	-	N.A.			86	-	-	-		-	-	Loans	1 Year SOFR + 240 BPS	5 Year	Unsecured	Business Purpose
		Zydus Wellness International DMCC	Subsidiary Company	Loan	ļ	-	N.A.			52	-	-	-		-	-	Loans	1 Year SOFR + 210 BPS	5 Year	Unsecured	Business Purpose
225	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan	ļ	-	N.A.			30	-		-		-	-	-	-	-	-	-
226	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		-	N.A.			1,520	-	-	-		-	-	-	-	-	-	-
227	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	5	-	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be counterparty approved by committee ratification Opening Closing advance/ Secured/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any othe funds (endusage) subsidiary investment etc.) Zvdus Wellness Products Subsidiary Purchase of goods or 228 Naturell (India) Private Limited N.A mited Company ervices Zydus Wellness Products Subsidiary Sale of goods or 229 Naturell (India) Private Limited N.A imited ompany ervices Zydus Wellness Products Subsidiary Purchase of fixed 230 Naturell (India) Private Limited N.A Limited Company Outstanding Zydus Wellness International ubsidiary Any other 231 Zydus Wellness Limited Receivables NΑ 243 359 DMCC transaction Company Outstanding Subsidiary Any other Zvdus Wellness Products Zydus Wellness Limited Payables - Other 44 55 N.A imited ransaction Company than loans Zydus Wellness Products Subsidiary Any other Outstanding 233 Zydus Wellness Limited N.A 440 1,133 imited Company transaction Payables - Loan Outstanding Zvdus Wellness International Subsidiary Any other 234 Zydus Wellness Limited Receivables -N.A 35 45 Company transaction Other than loan: Zydus Wellness Products Purchase of goods or Subsidiary 235 Zydus Healthcare Limited ompany Enterprises significantly 7vdus Wellness Products Cadmach Machinery Company influenced by Purchase of fixed 236 N.A Limited Private Limited Directors and/ assets or their relatives Enterprises significantly Zydus Wellness Products Mukesh M. Patel & Co., nfluenced by Purchase of goods or 237 imited roprietorship Firm Directors and/ services or their relatives Key Zydus Wellness Products 238 Mr. Tarun Arora Managerial 37 temuneration imited Personnel Zydus Wellness Products Zydus Wellness International Subsidiary Sale of goods or 239 139 imited DMCC ompany ervices Zvdus Wellness Products Subsidiary Sale of goods or 240 Zydus Healthcare Limited N.A. 39 mited ompany ervices Zydus Wellness Products Zydus Wellness International Subsidiary Sale of goods or 241 Company services vdus Wellness Products Sale of goods or Subsidiary 242 Zvdus Healthcare Limited 11 N.A mited services ompany Reimbursement Subsidiary Zydus Wellness Products Zvdus Wellness International Any other 243 of Expenses N.A 10 imited Company transaction nterprises ignificantly Zydus Hospitals and Sale of goods or Zydus Wellness Products nfluenced by 244 Healthcare Research Private N.A Limited Directors and/ services Limited or their relatives ydus Wellness Products LM Manufacturing India Subsidiary Sale of goods or 245 Private Limited imited ompany ervices Reimbursement Subsidiary Zydus Wellness Products LM Manufacturing India Any other 246 of Expenses N.A Limited Private Limited Company transaction Recovered

0

Outstanding

Receivables -

Other than loan

N.A.

Zvdus Wellness Products

247

Limited

LM Manufacturing India

Private Limited

Subsidiary

Company

Anv other

transaction

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Nature of Details of other party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be Secured/ counterparty approved by committee ratification Opening Closing advance/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister balance the audit was balance intercorpora Unsecured of debt/ ndebtedness Itimate recipient of committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) Contributions during the year Zydus Wellness Products Heinz India Private Limited Any other 248 fincludes mployment N.A Limited Pension Fund ransaction Benefit Plans Employee's share and contribution Contributions Zvdus Wellness Sikkim during the year Post Zydus Wellness Products Any other 249 Employees Group Gratuity Employment [includes 16 Limited transaction Renefit Plans Scheme Employee's share and contribution Enterprises significantly Zydus Wellness Products Cadmach Machinery Company influenced by Purchase of goods or 250 N.A. Limited Private Limited Directors and/ services or their elatives Outstanding Zydus Wellness Products Zvdus Wellness International ubsidiary Any other 251 Receivables -214 176 N.A imited DMCC transaction `ompany Other than loans Outstanding Zydus Wellness Products Subsidiary Any other 252 Zydus Healthcare Limited Receivables -N.A. 20 17 imited Company transaction Other than loan: German Remedies Pharma Subsidiary Sale of goods or 253 Zvdus Healthcare Limited NΑ 152 Private Limited ervices ompany Subsidiary German Remedies Pharma Sale of goods or 254 Zydus Foundation N.A. 2 Private Limited Company ervices Outstanding Subsidiary Any other German Remedies Pharma 255 Receivables -Zydus Foundation N.A. 1 Private Limited Company transaction Other than loans German Remedies Pharma 1 Month T Bill + 150 arent 256 Zydus Lifesciences Limited Loan N.A. 1,000 Loans 5 Year Unsecured **Business Purpose** Private Limited ompany German Remedies Pharma Recon Pharmaceuticals and Subsidiary Any other Share of profit 257 N.A. Private Limited nvestments ompany ransaction Received Outstanding German Remedies Pharma Subsidiary Any other 258 Zydus Healthcare Limited Receivables -18 Private Limited Company transaction Other than loan Enterprises ignificantly Zydus Infrastructure Private nfluenced by Purchase of goods or 259 Zydus Pharmaceuticals Limited 22 Limited Directors and/ services or their relatives Zvdus Animal Health and Subsidiary Purchase of goods or 260 Zydus Pharmaceuticals Limited N.A Investments Limited Company services Zydus Lifesciences Global FZE Subsidiary Sale of goods or 261 Zvdus Pharmaceuticals Limited N.A. [UAE] ompany services Enterprises

ignificantly

nfluenced by

Directors and/

or their relatives Purchase of goods or

services

N.A

Vitely Corp Pvt Ltd (Formerly

Known Vitely Bio LLP)

262 Zydus Pharmaceuticals Limited

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction Meeting Nature approval by indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as tibuc where the transactions ratified by reporting ess (loan/ Details of the funds will be ounterparty approved by committee ratification Opening Closing advance/ Secured/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any othe funds (endusage) subsidiary investment etc.) Enterprises ignificantly Outstanding 263 Zydus Pharmaceuticals Limited Zydus Infrastructure Private nfluenced by Any other Payables - Other 9 Directors and/ transaction than loans or their relatives Outstanding Zydus Lifesciences Global FZE Subsidiary Any other 264 Zydus Pharmaceuticals Limited Receivables -NΑ 15 4 Company transaction Other than loan: Enterprises significantly Zydus Animal Health and Cadmach Machinery Company influenced by Purchase of goods or 265 N.A nvestments Limited Private Limited Directors and/ services or their relatives ydus Animal Health and Subsidiary 266 Dialforhealth Unity Limited nterest received vestments Limited ompany Outstanding Zydus Animal Health and ubsidiary Any other 267 Dialforhealth Unity Limited Receivables -NΑ n Investments Limited Company transaction Zydus Animal Health and 268 6,708 Sterling Biotech Limited loint Venture Investment N.A vestments Limited Zydus Animal Health and Biochem Pharmaceutical Subsidiary 269 nvestment N.A 1 Investment N.A N.A Unsecured **Business Purpose** nvestments Limited rivate Limited Company Zydus Animal Health and ydus Medtech Private Subsidiary 270 nterest received 45 nvestments Limited Limited Company Zydus Animal Health and Zydus Medtech Private Subsidiary 1 Month T Bill + 120 271 oan 988 Loans 5 Year Unsecured **Business Purpose** nvestments Limited imited ompany nterprises ignificantly Zydus Animal Health and Zydus Infrastructure Private influenced by Purchase of goods or 272 N.A Investments Limited Limited Directors and/ services or their relatives ydus Animal Health and Subsidiary Sale of goods or 273 7vVet Animal Health Inc NΑ 507 nvestments Limited Company ervices Zydus Animal Health and 274 Viona Pharmaceuticals INC nterest received N.A 11 nvestments Limited ompany Zydus Animal Health and 1 Month T Bill + 120 arent 275 ydus Lifesciences Limited N.A. 7,498 Loans 5 Year Unsecured **Business Purpose** vestments Limited ompany Outstanding Zydus Animal Health and Subsidiary Any other 276 173 403 7vVet Animal Health Inc Pavables - Othe N.A. Investments Limited transaction Company than loans Enterprises significantly Zydus Animal Health and Cadmach Machinery Company influenced by Purchase of goods or 277 N.A nvestments Limited Private Limited Directors and/ services or their elatives Enterprises significantly Outstanding Zydus Animal Health and Cadmach Machinery Company influenced by Any other Payables - Other N.A. 0 Investments Limited Private Limited Directors and/ transaction than loans or their relatives Enterprises ignificantly Outstanding Zydus Animal Health and Zydus Infrastructure Private nfluenced by Any other 279 Pavables - Othe N.A 3 Investments Limited Directors and/ transaction Limited than loans or their

					•										once, dur	ing the repo	orting period v	when such transaction	was underta	iken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monies either party as the trans	s a result of	in case an	y financials ind nake or give loa				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
280	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	427	444	-		-	-	-	-	-	-	-
281	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	1,033	2,036	-		-	-	-	-	-	-	-
282	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	860	428	-		-	-	-	-	-	-	-
283	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives			-	N.A.			26	-	-	-		-	-	-	-	-	-	-
284	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			111	-	-	-		-	-	-	-	-	-	-
285	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			247	-	-	-		-	-	-	-	-	-	-
286	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			223	-	-	-		-	-	-	-	-	-	-
287	Zydus Pharmaceuticals (USA)	Zydus Healthcare (USA) LLC	Subsidiary Company	Loan		-	N.A.			294	-	-	-		-	-	-	-	-	-	-
288	Zydus Pharmaceuticals (USA)	Sentynl Therapeutics Inc.	Subsidiary	Sale of goods or services		-	N.A.	<u> </u>		3	-	-	-		-	-	-	-	-	-	-
289	Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Subsidiary	Sale of goods or		-	N.A.			3	-		† -		-			-	 -	-	-
290	Inc. Zydus Pharmaceuticals (USA)	ZyVet Animal Health Inc	Subsidiary	services Sale of goods or	 	-	N.A.	 		3	-				-	-	-	-		-	-
291	Inc. Zydus Pharmaceuticals (USA)	Zydus Lifesciences Global FZE	Company Subsidiary	services Purchase of goods or	 		N.A.	·		4,079					-		-	-		-	
292		[UAE] Zydus Lifesciences Global FZE [UAE]	Company Subsidiary Company	services Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	 		1,185	-	-	-		-	-	-	-	-	-	
293		Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	79	-		-	-	-	-	-	-	-
294	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	4,357	5,109	-		-	-	-	-	-	-	-
295	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-

															once, dur	ing the repo	rting period w	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
296	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	-	N.A.			12	-	-	-		-	1	-	-	-	-	-
297	Zydus Pharmaceuticals (USA) Inc.		Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1	-	-	-		-	-	-	-	-	-	-
298	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1	-	-	-		-	-	-	-	-	-	-
299	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1	-	-	-		-	-	-	-	-	-	-
300	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
301	Zydus Pharmaceuticals (USA) Inc. Zydus Pharmaceuticals (USA)	Zydus Therapeutics INC	Subsidiary Company Subsidiary	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	6 Month SOFR + 50	-	-	-
302	Inc.	Zydus Healthcare (USA) LLC	Company	Loan		-	N.A.	ļ 		78	-	-	-		-	-	Loans	BPS BPS	1 Year	Unsecured	Business Purpose
303	Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Interest received		-	N.A.	ļ		6	-	-	-		-	-	-	-	-	-	-
304	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.			66	-	-	-		-	-	-	-	-	-	-
305	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Interest received		-	N.A.			25	-	-	-		-	-	-	-	-	-	-
306	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Interest received		-	N.A.			12	-	-	-		-	-	-	-	-	-	-
307	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Interest received		-	N.A.			214	-	-	-		-	-	-	-	-	-	-
308	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.		Any other transaction	Reimbursement of Expenses	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
309	Zydus Pharmaceuticals (USA)	Zydus Pharmaceuticals Canada		Interest received	Recovered	-	N.A.			2	-	-	† -		-		-	-		-	-
310	Zydus Pharmaceuticals (USA)	Zydus Pharmaceuticals Canada		Loan		-	N.A.	<u> </u>		43	-	-	 		-	-	Loans	3 Month SOFR + 50	1 Year	Unsecured	Business Purpose
311	Inc. Zydus Pharmaceuticals (USA) Inc.	Inc. Zydus Pharmaceuticals Canada Inc.	Company Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	51	98	-		-	-	-	-	-	-	-
312	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-
313	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Loan		-	N.A.			210	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
314	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Loan		-	N.A.			199	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
315	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Loan		-	N.A.	·	 	1,475	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
316	Zudus Pharmacouticals (LISA)	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.		•	-	16	27	-		-	-	-	-	-	-	-

Zydus Lifesciences Limited Disclosure of related party transactions for the half year/ six months ended September 30, 2025 Amount in INR Million except stated otherwise
Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa	ebtedness is i	ncurred to		Details o	f loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
317	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	75	-		-	-	-	-	-	-	-
318	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	46	133	-		-	-	-	-	-	-	-
319	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	89	99	-		-	-	-	-	-	-	-
320	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	2,765	2,876	-		-	-	-	-	-	-	-
321	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	941	1,193	-		-	-	-	-	-	-	-
322	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	368	586	-		-	-	-	-	-	-	-
323	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	8,120	9,949	-		-	-	-	-	-	-	-
324	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	33	2	-		-	-	-	-	-	-	-
325	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	7	-		-	-	-	-	-	-	-
326	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	4	-		-	-	-	-	-	-	-
327	Zydus Pharmaceuticals (USA) Inc.	Zylidac Bio LLC, USA	Subsidiary Company	Loan		-	N.A.			1	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
328	Zydus Pharmaceuticals (USA) Inc.	Zylidac Bio LLC, USA	Subsidiary	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-
329	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	33	39	-		-	-	-	-	-	-	-
330	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			174	-	-	-		-	-	-	-	-	-	-
331	Zydus Worldwide DMCC	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			1	-	-	-		-	-	-	-	-	-	-
332	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services	 	-	N.A.			1,076	-	-	-		-	-	-	-	-	-	-
333	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.			23	-	-	-		-	-	-	-	-	-	-
334	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Interest received		-	N.A.			13	-	-	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of th make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Details of other Nature of party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be counterparty approved by committee ratification Opening Closing advance/ Secured/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance ntercorpora Unsecured of debt/ ndebtedness timate recipient o committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) ubsidiary 335 Zydus Worldwide DMCC Zydus Netherlands B.V. 10 10 N.A N.A nvestment N.A Business Purpose Investment Insecured ompany Subsidiary Zydus Worldwide DMCC 336 Zydus France, SAS nterest received N.A ompany Outstanding ubsidiary Any other Zydus Worldwide DMCC 337 Zydus France, SAS Receivables N.A 216 228 Company transaction Loans Zvdus International Private Subsidiary 338 Zydus Worldwide DMCC nterest received NΑ 125 imited ompany Outstanding Alidac Healthcare (Myanmar) Subsidiary Anv other Zydus Worldwide DMCC 587 339 Receivables 553 N.A imited transaction Company Loans Outstanding Subsidiary Any other 340 Zydus Worldwide DMCC Zydus Netherlands B.V. Receivables -982 1,044 transaction Company Outstanding Zydus Lifesciences Global FZE Subsidiary Any other 341 Zydus Worldwide DMCC Payables - Other N.A. 0 [UAE] transaction Company than loans Outstanding Zydus Pharmaceuticals (USA) Subsidiary Any other Zydus Worldwide DMCC 288 Payables - Other 179 N.A ransaction than loans Outstanding Zydus Pharmaceuticals (USA) Subsidiary Any other 343 Zvdus Worldwide DMCC Receivables -797 N.A. transaction Company Other than loans Outstanding Zydus Pharmaceuticals Canada Subsidiary Any other 344 Viona Pharmaceuticals INC Receivables -N.A Company transaction Other than loan Outstanding Subsidiary Any other Viona Pharmaceuticals INC Zvdus Worldwide DMCC Receivables -Company transaction Other than loan Zydus Pharmaceuticals (USA) Subsidiary Sale of goods or 346 Zydus Healthcare (USA) LLC N.A. 19 ervices Subsidiary Sale of goods or 347 Zydus Healthcare (USA) LLC Zydus Therapeutics INC N.A. Company ervices Outstanding ydus Pharmaceuticals (USA) Subsidiary Any other 348 Zydus Healthcare (USA) LLC Receivables -N.A. 3 Company ransaction Other than loan Subsidiary Any other Outstanding Zydus Pharmaceuticals (USA) 349 Zydus Healthcare (USA) LLC N.A. 214 Payables - Loan Company transaction Outstanding Zydus Pharmaceuticals (USA) Subsidiary Any other 350 Zydus Healthcare (USA) LLC Payables - Other N.A 0 Company transaction than loans Outstanding Subsidiary Any other 351 Zydus Healthcare (USA) LLC Zydus Therapeutics INC Receivables transaction Company Other than loan: Outstanding Subsidiary Any other 352 Zydus Healthcare (USA) LLC Zvdus Worldwide DMCC Receivables -NΑ 2 Company transaction Other than loan: Reimhursement Zydus Animal Health and ubsidiary Any other 353 ZyVet Animal Health Inc of Expenses 218 nvestments Limited Company ransaction Recovered Zvdus Wellness International Subsidiary Purchase of goods or

N.A.

354

DMCC

Zydus Worldwide DMCC

Company

															once, dur	ing the repo	rting period w	hen such transaction	was underta	aken.	
	Details of the party entering into	Details of the counter	rparty			Value of the		Value of the	Date of		In case monies	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
	the transaction		1			related party	Remarks on	related	Audit Committee	Value of	the trans	action			-				•		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	transaction as approved by the audit committee	approval by audit committee	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
355	Zydus Wellness International DMCC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-
356	Zydus International Private Limited	RIC Chemicals LTD	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-	-
357	Limited	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-
358	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-
359	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.			7	-	-	-		-	-	-	-	-	-	-
360	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-
361	Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Loan		-	N.A.			5,499	-	-	-		-	-	-	-	-	-	-
362	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.			5,186	-	-	-		-	-	-	-	-	-	-
363	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.			22	-	-	-		-	-	-	-	-	-	-
364	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables -	-	N.A.			-	5,421	-	-		-	-	-	-	-	-	-
365	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received	Loans	-	N.A.	 		424	-	-	-		-		-	-	-	-	-
366	Zydus International Private		Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	17,115	18,220	-		-	-	-	-	-	-	-
367	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	5,417	427	-		-	-	-	-	-	-	-
368	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	256	294	-		-	-	-	-	-	-	-
369	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	368	419	-		-	-	-	-	-	-	-
370	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	455	503	-		-	-	-	-	-	-	-
371	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	338	385	-		-	-	-	-	-	-	-
372	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
373	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-	<u>.</u>	-	-	-	-	-	-	-
374		Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	421	466	-		-	-	-	-	-	-	-
375		Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	51	57	-		-	-	-	-	-	-	-
376	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		-	N.A.			450	-	-	-		-	-	-	-	-	-	-

													intercorpor	ate deposits, at				by the listed entity/su when such transaction			a to be disclosed only
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials indo ake or give loar				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
377	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-
378	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	7	15	-		-	-	-	-	-	-	-
379	Zydus Pharmaceuticals Mexico SA De CV	Zydus Pharmaceuticals Mexico Services Company SA De C.V.	Subsidiary Company	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
380	Zydus Healthcare Philippines Inc.	RJ Conception Law Office	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-
381	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-
382	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	-	-		-	-	-	-	-	-	-
383	Zynext Ventures Pte. Ltd.	Zynext Ventures USA LLC	Subsidiary Company	Investment		-	N.A.			-	781	-	-		-	-	-	-	-	-	-
384	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Interest received		-	N.A.			26	-	-	-		-	-	-	-	-	-	-
385	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Interest received		-	N.A.			48	-	-	-		-	-	-	-	-	-	-
386	Zydus Pharmaceuticals UK Ltd.	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	-	-		-	-	-	-	-	-	-
387	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Loan		-	N.A.			905	-	-	-		-	-	-	-	-	-	-
388	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	9	64	-		-	-	-	-	-	-	-
389	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	1,704	911	-		-	-	-	-	-	-	-
390	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	769	856	-		-	-	-	-	-	-	-
391	[UAE]	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	3,084	5,054	-	·	-	-	-	-	-	-	-
392	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			314	-	-	-		-	-	-	-	-	-	-
393	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		-	N.A.			13	-	-	-		-	-	-	-	-	-	-
394	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			8	-	-	-		-	-	-	-	-	-	-

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of th make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Nature of Details of other party transaction Relationship Type of Related ransaction approval by Meeting Nature indebted Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be Secured/ ounterparty approved by committee ratification Opening Closing advance/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) Outstanding Zydus Lifesciences Global FZE Any other ubsidiary 395 Zydus Healthcare (USA) LLC Payables - Other 22 UAE] ransaction than loans Outstanding Zydus Lifesciences Global FZE ubsidiary Any other 396 Viona Pharmaceuticals INC Receivables -166 267 N.A UAE] transaction ompany Other than loan Reimbursement Subsidiary Any other 397 LM Manufacturing Limited Zydus Pharmaceuticals UK Ltd. of Expenses 31 company transaction Recovered ubsidiary Sale of goods or 398 LM Manufacturing Limited Zydus Pharmaceuticals UK Ltd. 15 ubsidiary Sale of goods or 399 LiqMeds Worldwide Limited LM Manufacturing Limited N.A. ompany ervices Outstanding Subsidiary Any other 400 LiqMeds Worldwide Limited LiqMeds Lifecare Limited Receivables -N.A. 20 ransaction Company Other than loan: Outstanding Subsidiary Any other LigMeds Worldwide Limited 44 LigMeds Limited Receivables -N.A ransaction Other than loan Purchase of goods or 402 LM Manufacturing Limited Oncosol Limited oint Ventures N.A. ervices Sale of goods or 403 LM Manufacturing Limited Oncosol Limited Sale of goods or LigMeds Lifecare Limited Oncosol Limited oint Venture services LM Manufacturing India Subsidiary Sale of goods or 405 LM Manufacturing Limited N.A 36 rivate Limited ompany ervices Outstanding ubsidiary Any other 406 LigMeds Worldwide Limited LM Manufacturing Limited Receivables -937 2,400 ompany transaction Other than loan Outstanding Any other 407 LigMeds Worldwide Limited Oncosol Limited Joint Ventures Receivables -N.A 0 ransaction Other than loan: Outstanding Subsidiary Any other 408 LM Manufacturing Limited Medsolutions (Europe) Limited Payables - Other N.A Company ransaction than loans Outstanding Subsidiary Any other 409 LM Manufacturing Limited Zydus Pharmaceuticals UK Ltd. Receivables N.A. ransaction Other than loan Outstanding Any other 410 LM Manufacturing Limited Oncosol Limited Joint Venture Receivables -2 N.A ransaction Other than loan Outstanding ubsidiary Any other 411 LiqMeds Limited LM Manufacturing Limited Receivables -N.A 340 485 ompany transaction Other than loans Outstanding ubsidiary Any other 412 LiqMeds Lifecare Limited LM Manufacturing Limited Receivables -37 38 ompany ransaction Other than loan Outstanding Subsidiary Any other LM Manufacturing India 413 13 9 LM Manufacturing Limited Receivables -N.A. Private Limited Company transaction

Other than loans

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either party as a result of Details of loans/ investments /alue of th make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Nature of Details of other party transaction Relationship Type of Related ransaction approval by Meeting Nature indebtedr Purpose for which related party ransactio during the of the (loan/ No **Party Transaction** as audit where the transactions ratified by reporting ess (loan/ Details of the funds will be Secured/ ounterparty approved by committee ratification Opening Closing advance/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) Outstanding Any other Subsidiary LigMeds Lifecare Limited iqMeds Limited Receivables -Company ransaction Other than loan Outstanding Subsidiary Any other 415 LigMeds Lifecare Limited Medsolutions (Europe) Limited Receivables -10 11 N.A. transaction Other than loan Outstanding Any other 416 LigMeds Lifecare Limited Oncosol Limited Joint Ventures 117 117 Receivables -N.A transaction Other than loans Outstanding Any other ubsidiary 417 Medsolutions (Europe) Limited LigMeds Worldwide Limited Receivables -N.A. 13 14 Company transaction Other than loan Outstanding Any other 418 Medsolutions (Europe) Limited Oncosol Limited Joint Ventures Receivables -N.A. 1 transaction Other than loan: Enterprises ignificantly Zydus Medtech Private influenced by Purchase of fixed Zydus Infrastructure Private 419 1,037 N.A Limited Limited Directors and/ assets or their relatives Zydus Medtech Private Subsidiary 420 Zvdus Medtech France SAS nvestment NΑ 202 202 Investment N.A N.A Unsecured **Business Purpose** imited ompany significantly Zvdus Hospitals and Zydus Medtech Private Purchase of goods or nfluenced by 421 Healthcare Research Private Limited Directors and/ services Limited or their relatives Zydus Lifesciences Global FZE Subsidiary Any other Reimbursement Zydus Worldwide DMCC [UAE] ompany ransaction of Expenses paid Outstanding Zydus Lifesciences Global FZE Subsidiary Any other 423 Zydus Worldwide DMCC Receivables -NΑ 1.249 transaction Company Other than loans Enterprises significantly Purchase of goods or influenced by 424 Zydus Healthcare S.A. (Pty) Ltd DI Consultancy N.A 12 Directors and/ services or their relatives Subsidiary 3 Month EURIBOR 425 7,276 7 Year **Business Purpose** Zvdus Medtech France SAS Amplitude Surgical SAS nan NΑ Loans Unsecured 150 BPS Company ubsidiary 426 Zydus Medtech France SAS mplitude Surgical SAS nterest received N.A. 44 ompany Outstanding Subsidiary Any other 427 Zydus Medtech France SAS Amplitude Surgical SAS Receivables 7,606 Company transaction oans Subsidiary 3 Month EURIBOR -428 Zydus Medtech France SAS mplitude SAS [France] N.A. 1,321 7 Year Unsecured **Business Purpose** Company 50 BPS Subsidiary Zydus Medtech France SAS implitude SAS [France] nterest received N.A. Company Outstanding Subsidiary Any other 430 Zydus Medtech France SAS Amplitude SAS [France] Receivables 1,381 Company ransaction Subsidiary Purchase of goods or

20

N.A.

Amplitude SAS [France]

SCI Les Tilleuls [France]

No

462

Amplitude SAS [France]

Subsidiary

Company

SCI Les Tilleuls [France]

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to In case any financials indebtedness is incurred to Details of the counterparty Value of the Date of either narty as a result of Details of loans/ investments /alue of the make or give loans/ investments the transaction related Audit the transaction related Value of Committee party Remarks on Details of other Nature of party transaction Relationship Type of Related ransaction Meeting Nature approval by indebtedr Purpose for which related party ransactio during the of the (loan/ **Party Transaction** as audit where the transactions ratified by ess (loan/ Details of the funds will be reporting counterparty approved by committee ratification Opening Closing advance/ Secured/ other Interest Rate (%) utilised by the Name Name the audit issuance Cost Tenure Tenure period with the lister the audit was balance balance intercorpora Unsecured of debt/ ndebtedness ltimate recipient o committee entity or its te deposit/ committee approved any other funds (endusage) subsidiary investment etc.) ubsidiary Purchase of goods or 432 Amplitude SAS [France] SCI SOFAB FALLA [France] N.A 9 ompany ervices Amplitude Ile de France Subsidiary Purchase of goods or 433 Amplitude SAS [France] 33 N.A France] ompany ervices Duotech Amplitude SAS Subsidiary Purchase of goods or 434 Amplitude SAS [France] N.A 15 France] Company ervices ubsidiary Purchase of goods or 435 mplitude SAS [France] implitude Sud SAS [France] 24 ompany ervices Subsidiary Purchase of goods or 436 Amplitude SAS [France] implitude Nord SAS [France] 26 ompany ervices Ortho Santé (Amplitude Subsidiary Purchase of goods or 437 Amplitude SAS [France] 30 Ouest) [France] Company ervices Amplitude Australia Pty Ltd Subsidiary Sale of goods or 438 Amplitude SAS [France] N.A. 55 [Australia] ompany ervices mplitude South Africa Ptv Ltd Subsidiary Sale of goods or 439 Amplitude SAS [France] 11 NΑ South Africal company ervices Amplitude Latin America SA Subsidiary Sale of goods or 440 Amplitude SAS [France] N.A 21 Brazil1 ervices ompany Subsidiary Sale of goods or 441 35 Amplitude SAS [France] Amplitude Benelux [Belgium] N.A ompany ervices mplitude Suisse SA ubsidiary Sale of goods or 442 Amplitude SAS [France] N.A. witzerlandl ompany ervices ale of goods or ubsidiary 443 Amplitude SAS [France] mplitude GmbH [Germany] N.A. Company services mplitude Ile de France Subsidiary Sale of goods or 444 Amplitude SAS [France] N.A. ompany ervices Subsidiary Sale of goods or 445 Amplitude SAS [France] implitude Sud SAS [France] N.A 0 ompany ervices ubsidiary Sale of goods or 446 Amplitude SAS [France] N.A. Amplitude Nord SAS [France] services Company Ortho Santé (Amplitude ubsidiary Sale of goods or 447 Amplitude SAS [France] NΑ Duest) [France] Company ervices ubsidiary sale of goods or 448 Amplitude SAS [France] Amplitude Benelux [Belgium] NΑ ompany ervices mplitude Orthopedics Subsidiary 449 Amplitude SAS [France] nterest received N.A. orporation [USA] ompany Amplitude Australia Pty Ltd Subsidiary 450 Amplitude SAS [France] nterest received N.A. Australia] ompany mplitude South Africa Ptv Ltd Subsidiary 451 Amplitude SAS [France] nterest received N.A. outh Africal ompany Subsidiary 452 Amplitude SAS [France] N.A. mplitude Benelux [Belgium] nterest received Company mplitude Suisse SA Subsidiary 453 Amplitude SAS [France] nterest received N.A Switzerland] Company ubsidiary 454 Amplitude SAS [France] mplitude GmbH [Germany] nterest received N.A ompany Subsidiary 455 Amplitude SAS [France] SCI Les Tilleuls [France] nterest paid NΑ Company ubsidiary 456 Amplitude SAS [France] SCI SOFAB FALLA [France] nterest paid N.A ompany mplitude Ile de France ubsidiary 457 Amplitude SAS [France] nterest paid N.A. 0 France] Company Duotech Amplitude SAS Subsidiary 458 Amplitude SAS [France] ompany Subsidiary 459 Amplitude SAS [France] implitude Sud SAS [France] ompany Subsidiary 460 Amplitude SAS [France] implitude Nord SAS [France] 0 Company Ortho Santé (Amplitude Subsidiary 461 Amplitude SAS [France] 0 Ouest) [France] Company

289

Zydus Lifesciences Limited Disclosure of related party transactions for the half year/ six months ended September 30, 2025 Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party entering In case monies are due to

	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of the related	Date of Audit	Value of	In case monie either party a the trans	s a result of		y financials inde ake or give loar				Details o	f loans/ inve	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by the audit committee	Committee Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
463	Amplitude SAS [France]	SCI SOFAB FALLA [France]	Subsidiary Company			-				-	-	11	-		-	-	-	-	-	-	-
464	Amplitude SAS [France]	Amplitude Ile de France	Subsidiary			-			 	-	-	35	-			-	-	-	-	-	
465		[France] Duotech Amplitude SAS	Company Subsidiary									40	 								
		[France]	Company Subsidiary										ļ								
466	Amplitude SAS [France]	Amplitude Sud SAS [France]	Company			-				-	-	79	-		-	-	-	-	-	-	-
467	Amplitude SAS [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				-	-	30	-		-	-	-	-	-	-	-
468	Amplitude SAS [France]	Ortho Santé (Amplitude Ouest) [France]	Subsidiary Company			-				-	-	68	-		-	-	-	-	-	-	-
469	Amplitude SAS [France]	Amplitude Latin America SA	Subsidiary						 -	-		0	-		-	-	-	-	-		-
470		[Brazil] SCI Les Tilleuls [France]	Company Subsidiary						 			14	 -			L				 	
			Company Subsidiary									14	ļ								
471	Amplitude SAS [France]	SCI SOFAB FALLA [France]	Company			-			 	-	-	4	-		-	-	-	-	-	-	-
472	Amplitude SAS [France]	Amplitude lle de France [France]	Subsidiary Company			-				-	-	41	-		-	-	-	-	-	-	-
473	Amplitude SAS [France]	Duotech Amplitude SAS [France]	Subsidiary Company			-				-	-	19	-		-	-	-	-	-	-	-
474	Amplitude SAS [France]	Amplitude Sud SAS [France]	Subsidiary			-			l—	-	-	30	-		-	-	-	-	-	-	-
475	Amplitude SAS [France]	Amplitude Nord SAS [France]	Company Subsidiary									34	l								
		Ortho Santé (Amplitude	Company Subsidiary																		
476	Amplitude SAS [France]	Ouest) [France] Amplitude Orthopedics	Company Subsidiary						 	-		38	-	 	-		-	-		- 	-
477	Amplitude SAS [France]	Corporation [USA]	Company			-				-	-	638	-		-	-	-	-	-	-	-
478	Amplitude SAS [France]	Amplitude Australia Pty Ltd [Australia]	Subsidiary Company			-				-	-	2,035	-		-	-	-	-	-	-	-
479	Amplitude SAS [France]	Amplitude South Africa Pty Ltd [South Africa]	Subsidiary Company			-				-	-	492	-		-	-	-	-	-	-	-
480	Amplitude SAS [France]	SCI Les Tilleuls [France]	Subsidiary						 -	-		22	-		-	-	-	-	-	-	-
481		Amplitude Benelux [Belgium]	Company Subsidiary									221	l								
		Amplitude Suisse SA	Company Subsidiary						 				 				 				
482	Amplitude SAS [France]	[Switzerland]	Company			- 			 	-	-	137	-	 	-	-	-	-	-	- 	-
483	Amplitude SAS [France]	Amplitude GmbH [Germany]	Subsidiary Company			-			<u></u>	-	-	98	-		-	-	-	-	-	-	-
484	Amplitude SAS [France]	Amplitude Australia Pty Ltd [Australia]	Subsidiary Company			-				-	-	99	-		-	-	-	-	-	-	-
485	Amplitude SAS [France]	Amplitude South Africa Pty Ltd [South Africa]				-				-	-	12	-		-	-	-	-	-	-	-
486	Amplitude SAS [France]	Amplitude Latin America SA	Subsidiary							-		241	-		-		-	-	-	-	_
487		[Brazil] Amplitude Ile de France	Company Subsidiary						 			2	 								
		[France] Duotech Amplitude SAS	Company Subsidiary										ļ						<u> </u>	<u></u>	
488	Amplitude SAS [France]	[France]	Company			-			 	-	-	0	-		-	-	-	-	-	-	-
489	Amplitude SAS [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				-	-	1	-		-	-	-	-	-	-	-
490	Amplitude SAS [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				-	-	1	-	-	-	-	-		-	-	-
491	Amplitude SAS [France]	Ortho Santé (Amplitude	Subsidiary							-	-	53	-		-	-	-	-	-	-	-
492	Amplitude SAS [France]	Ouest) [France] Amplitude Benelux [Belgium]	Company Subsidiary									47						-	-		-
		Amplitude Suisse SA	Company Subsidiary										 -			L				 	
493	Amplitude SAS [France]	[Switzerland]	Company			- 		<u> </u>	<u> </u>	-	-	5	<u></u>	<u> </u>	-		-	-	-		-

Zydus Lifesciences Limited

Disclosure of related party transactions for the half year/ six months ended September 30, 2025

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

															once, dui	ring the repo	orting period w	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related	Remarks on	Value of the related	Date of Audit Committee	Value of	In case monie either party a the trans	s a result of		y financials ind nake or give load				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	approval by audit committee	party transaction ratified by the audit committee	Meeting where the ratification was approved	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
494	Amplitude SAS [France]	Amplitude GmbH [Germany]	Subsidiary Company			-				-	-	1	-		-	-	-	-	-	-	-
495	Amplitude Surgical SAS	Amplitude SAS [France]	Subsidiary Company			-				32	-	-	-		-	-	-	-	-	-	-
496	Amplitude Surgical SAS	Amplitude SAS [France]	Subsidiary Company		<u> </u>	-		<u> </u>	<u> </u>	17	-	-	-		-	-	-	-		-	-
497	Amplitude Surgical SAS	SCI Les Tilleuls [France]	Subsidiary Company		<u> </u>	-		<u> </u>	<u> </u>	1	-	-	-		-	-	-	-	-	-	
498	Amplitude Surgical SAS	Amplitude SAS [France]	Subsidiary Company		<u> </u>	-		<u> </u>	<u> </u>	-	-	3,526	-		-	-	-	-	-	-	
499	Amplitude Surgical SAS	SCI Les Tilleuls [France]	Subsidiary Company		<u> </u>	-		<u> </u>	<u> </u>	-	-	261	-		-	-	-	-		-	-
500	Amplitude lle de France [France]	Amplitude Sud SAS [France]	Subsidiary Company	·		-		†	1	0	-	-	-		-	-	-	-	-	-	-
501	Amplitude lle de France [France]	Duotech Amplitude SAS [France]	Subsidiary Company	·		-	 	†	<u> </u>	0	-	-	-		-	-	-	-	-	-	-
502	Amplitudo II o do Eranco	Amplitude Sud SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	-
503	Amplitude lle de France [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				0	-	-	-		-	-	-	-	-	-	-
504	Amplitude lle de France [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-
505	Amplitude lle de France [France]	Duotech Amplitude SAS [France]	Subsidiary Company	·		-	 	†	<u> </u>	-	-	0	-		-	-	-	-	-	-	-
506	Amplitude lle de France [France]	Amplitude Sud SAS [France]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-
507	Amplitude lle de France [France]	Amplitude Nord SAS [France]	Subsidiary Company			-				-	-	0	-		-	-	-	-	-	-	-
508	Comfort Click Softech Pvt. Ltd.	Comfort Click Limited (UK)	Subsidiary Company			-				64	-	-	-		-	-	-	-	-	-	-
509	Comfort Click Limited (UK)	Comfort Click Limited (Ireland)	Subsidiary Company			-				2	-	-	-		-	-	-	-	-	-	-
510	Comfort Click Limited (UK)	Comfort Click Limited (Ireland)	Subsidiary Company			-				7	-	-	-		-	-	-	-	-	-	-
511	Comfort Click Limited (UK)	Comfort Click Limited (Ireland)	Subsidiary Company			-				-	-	129	-		-	-	-	-	-	-	-
512	Comfort Click Limited (UK)	Comfort Click Softech Pvt. Ltd.	Subsidiary Company			-				-	-	9	-		-	-	-	-	-	-	-
							ı								,						

Notes:

- 1 Amount mentioned as 0 denotes value less than INR 1 Million.
- 2 Opening and closing balance are not given where there was no transaction of Investment during the half year ended September 30, 2025.
- 3 Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.